Table 1.
Comparison of Progression Features Between Patients with DH at Follow-Up (Group 1) and Patients with a DH at Baseline (Group 2)
| Progression | Group 1 (n=28)a |
Group 2 (n=38)a |
P valueb | 95% CI (Difference in Proportion) |
|---|---|---|---|---|
| Global Progression | 6 (21.4%) | 15 (39.5%) | 0.12 | −4.5% - 40.7% |
| PPA Progression | 2 (7.1%) | 8 (21.1%) | 0.17 | −3.7% - 31.7% |
| Superior PPA Progression | 1 (3.6%) | 7 (18.4%) | 0.13 | −1.5% - 31.1% |
| Inferior PPA Progression | 1 (3.6%) | 5 (13.2%) | 0.23 | −5.1% - 24.3% |
| RNFL Progression | 2 (7.1%) | 6 (15.8%) | 0.45 | −7.5% - 24.9% |
| Superior RNFL Progression | 1 (3.6%) | 5 (13.2%) | 0.23 | −5.1% - 24.3% |
| Inferior RNFL Progression | 1 (3.6%) | 3 (7.9%) | 0.63 | −8.3% - 16.9% |
| Rim Progression | 4 (14.3%) | 12 (31.6%) | 0.11 | −3.5% - 38.1% |
| Superior Rim Progression | 2 (7.1%) | 7 (18.4%) | 0.28 | −5.7% - 28.3% |
| Inferior Rim Progression | 3 (10.7%) | 6 (15.8%) | 0.72 | −11.4% - 21.6% |
a
Proportion of group represented as percentages of n
b
P values for Fisher's exact tests used for all categories of progression except global and rim progression. χ2 test used for global and rim progression